| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 0.1 | 0.0 | 0.2 |
| Total income | 0.1 | 0.0 | 0.2 |
| Profit before exceptional items & tax | 0.1 | 0.0 | 0.1 |
| Profit before tax | 0.1 | 0.0 | 0.1 |
| Net profit | 0.1 | 0.0 | 0.1 |
| Operating margin | 100.0% | 0.0% | 50.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +0.00% |
|---|---|
| Revenue, year on year | -50.00% |
Source
Read the filing ↗
BSE results filing, NSE: AMARDEE. Figures extracted from the filing.
Amerise Biosciences Ltd: key numbers
- Share price
- ₹0.81
- Market cap
- ₹5.35 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.02 Cr
- P/E (TTM)
- -101.4×Sector 29.0×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Amerise Biosciences Ltd
All →
16:27 IST
BSE
Annual General Meeting
Amerise Biosciences Annual General Meeting
Amerise Biosciences Limited conducted its 41st Annual General Meeting on September 24, 2026. Shareholders approved financial statements and the appointment of a new Wholetime Director and CFO.
17:23 IST
BSE
Financial Results
Amerise Biosciences Q1 FY27 Results: Net Loss of ₹0.1 Cr
Amerise Biosciences Ltd reported a net loss of ₹0.1 Cr for Q1 FY27.
- Key figure
- Net loss ₹0.1 Cr